Sean M. Fortier, MD
29 posts
@SeanFortierMD
Physician-Scientist Assistant Professor of Internal Medicine University of Michigan Medical School I treat lung disease and study fibroblasts.
A great step for #CureIPF!!! INTEGRIS-IPF, a phase IIa #RCT suggests that Bexotegrast, an αvβ6 & αvβ1 inhibitor has safety & dose-dependent efficacy. Can't wait for Phase III results. Kudos Drs Lancaster, Flaherty, #IntegrisIPF team & @ATSBlueEditor! doi.org/10.1164/rccm.2…
In this phase 2 trial involving adults with metabolic dysfunction–associated steatohepatitis and liver fibrosis, survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis. Full trial results: nej.md/4bBXQPF #EASLCongress
Scientists decipher the biochemical cues that shape the activity and diversity of GPCR signaling, our weekly Editors’ Choice piece dives into how bacterial LPS disrupts the blood-brain barrier, and more in this week’s new issue of #ScienceSignaling. scim.ag/7ct
A study in @NatImmunol finds that a single injection of CAR T cells, designed to target drivers of allergic reactions, represses the signs and symptoms of allergic asthma in mice for at least a year. go.nature.com/3VeWuVg
As #ATS2024 ends, we’re excited to release our new tool, AlveolEye, a free app which uses machine learning to make lung morphometry rigorous and less time consuming – a tool made by two amazing students Sam and Joe Hirsh, and @shawyonshirazi from the Sucre Lab @sucre_jen 🧵1/5
A @NatureCareers feature highlights how new data repositories and alternative journals and workshops offer routes for sharing negative results, which could help to solve the reproducibility crisis and give machine learning a boost. go.nature.com/3WEfmhH
